Tech Company Financing Transactions
Aegle Therapeutics Funding Round
Aegle Therapeutics, operating out of Miami, secured $4 million from New World Angels, DeepWork Capital and DEFTA Partners.
Transaction Overview
Company Name
Announced On
1/9/2020
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Undisclosed
Investors
New World Angels (Lead Investor) (David Schimmel)
DEFTA Partners (Elona Baum)
Tellus International (Lonnie Moulder)
Proceeds Purpose
The new funding validates our business plan and allows us to advance AGLE-102 into the clinic as well as expand the capabilities and opportunities of this cutting-edge platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1951 NW 7th Ave. 160 #152
Miami, FL 33136
USA
Miami, FL 33136
USA
Phone
Undisclosed
Website
Email Address
Overview
Aegle Therapeutics Corp. is a first in class, Phase 1/2a ready, biotechnology company isolating extracellular vesicles (EVs) from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions, including burns and epidermolysis bullosa (EB), a rare pediatric connective tissue disorder, and to prevent scarring.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shelley Hartman
Chief Scientific Officer
Evangelos Badiavas
Controller
Patricia Chicvara
VP - Operations
Heidi Kempinski
Browse more venture capital transactions:
Prev: 1/9/2020: Eyevensys venture capital transaction
Next: 1/9/2020: Porch venture capital transaction
Share this article
About Our VC Transactions Data
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs